Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice

Microbial Pathogenesis

Volumn 43, Issue 5-6, 2007, Pages 217-223

  Jamali, Abbas ^a   Mahdavi, Mehdi ^a   Shahabi, Shahram ^b   Hassan, Zuhair M ^a   Sabahi, Farzaneh ^a   Javan, Mohammad ^a   Farsani, Mohammad Jazayeri ^a   Parsania, Masoud ^c   Bamdad, Taravat ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Acquired immunity; Endogenous opioids; Herpes simplex virus 1; Naloxone; Viral infection

Indexed keywords

GAMMA INTERFERON; NALOXONE; NEUTRALIZING ANTIBODY; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEATH; DELAYED HYPERSENSITIVITY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HERPES; HERPES SIMPLEX VIRUS 1; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; MICE; MICE, INBRED BALB C; NALOXONE; RECEPTORS, OPIOID; VERO CELLS;

ANIMALIA; HUMAN HERPESVIRUS 1; MUS;

EID: 34548630585     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2007.06.001     Document Type: Article

References (34)

1. Roizman B., and Knipe M. Herpes simplex virus and their replication. Fields virology (2001), Lippicott Williams & Wilkins 2391-2510
2. Whitly R., and Roizman B. Herpes simplex virus infections. Lancet 357 (2001) 1513-1518
3. Koelle D.M., and Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16 (2003) 96-113
4. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., and Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Dependence 62 (2001) 111-123
5. Carpenter G.W., and Carr D.J. Pretreatmant with Funaltrexamince blocks morphine-mediated suppression of CTL activity in alloimmunized mice. Immunopharmacology 29 (1995) 129-140
6. Molitor T.W., Moilla A., Risdahl J.M., Murtaugh M.P., Chao C.C., and Peterson P.K. Chronic morphine administration impairs cell-mediated immuneresponses in swine. J Pharmacol Exp Ther 260 (1991) 581-586
7. Friedman H., Newton C., and Klein T.W. Microbial infection, immunodulation, and drugs of abuse. Clin Microbial Rev 16 (2003) 209-219
8. Alonzo N.C., and Carr D.J. Morphine reduces mortality in mice following ocular infection with HSV-1. Immunopharmacology 41 (1999) 187-197
9. Lioy D.T., Sheridan P.A., Hurley S.D., Walton J.R., Martin A.M., Olschowka J.A., et al. Acute morphine exposure potentiates the development of HSV-1-induced encephalitis. J Neuroimmunol 172 (2006) 9-17
10. Sheridan P.A., and Moynihan J.A. Modulation of the innate immune response to HSV-1 following acute administration of morphine: role of hypothalamo-pituitary-adrenal axis. J Neuroimmunol 158 (2005) 145-152
11. Davies P.W., Vallejo M.C., Shannon K.T., Amortegui A.J., and Ramanathan S. Oral herpes simplex reactivation after intrathecal morphine: a prospective randomized trial in an obstetric population. Anesth Analg 100 (2005) 1472-1476
12. Jamali A., Roostaee M.H., Soleimanjahi H., Ghaderi Pakdel F., and Bamdad T. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge. Comp Immunol Microbiol Infect Dis 30 (2007) 71-80
13. Nass P.H., Elkins K.L., and Weir J.P. Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection. Vaccine 19 (2001) 1538-1546
14. Roizman B., and Knipe M. Herpes simplex viruses. Fields virology (2001), Lippicott Williams & Wilkins 2480
15. Zawatzky R., Hilfenhaus R.J., Marcucci F., and Kirchner H. Experimental infection of inbred mice with herpes simplex virus 1 investigation of humoral and cellular immunity and of interferon induction. J Gen Virol 53 (1981) 31-38
16. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
17. Kirst A., Wack C., Lutz W.K., Eggert A., Kämpgen E., and Fischer W.H. Expression of functional k-opioid receptors on murine dendritic cells. Immunol Lett 84 (2002) 41-48
18. Refojo D., Kovalovsky D., Young J.I., Rubinstein M., Holsboer F., Reul J.M., et al. Increased splenocyte proliferative response and cytokine production in h-endorphin-deficient mice. J Neuroimmunol 131 (2002) 126-134
19. Shahabi N.A., and Sharp B.M. Antiproliferative effects of δ opioids on highly purified CD4+ and CD8+ murine T cells. J Pharmacol Exp Ther 273 (1995) 1105-1113
20. Sacerdote P., di San Secondo V.E., Sirchia G., Manfredi B., and Panerai A.E. Endogenous opioids modulate allograft rejection time in mice: possible relation with Th1/Th2 cytokines. Clin Exp Immunol 113 3 (1998) 465-469
21. Barcellini W., Sacerdote P., Borghi M.O., Rizzardi G.P., Fain C., De Giuli Morghen C., et al. Beta-endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. Peptides 15 5 (1994) 769-775
22. Sacerdote P., Manfredi B., Gaspani L., and Panerai A.E. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 95 (2000) 2031-2036
23. Yu Z., Manickan E., and Rouse B.T. Role of interferon-gamma in immunity to herpes simplex virus. J Leukoc Biol 60 (1996) 528-532
24. Geiger K.D., Nash T.C., Sawyer S., Krahl T., Patstone G., Reed J.C., et al. Interferon-γ protects against herpes simplex virus type 1-mediated neuronal death. Virology 238 (1997) 189-197
25. Vollstedt S., Arnold S., Schwerdel C., Franchini M., Alber G., Di Santo J.P., et al. interplay between alpha/beta and gamma interferons with B, T, and Natural Killer Cells in the Defense against Herpes Simplex Virus Type 1. J Virol 78 (2004) 3846-3850
26. Abaituaa F., Rodríguezc J.R., Garzóna A., Rodrígueza D., and Estebana M. Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 116 (2006) 11-20
27. Carr D.J., and Blalock J.E. Naloxone administration in vivo stereoselectively alters antigen-dependent and antigen-independent immune responses. Psychoneuroendocrinology 16 (1991) 407-415
28. Kishimoto C., Takada H., Hiraoka Y., and Shiraki K. Effects of naloxone, an opiate receptor antagonist, on coxsackievirus B3 myocarditis in the mouse. Cardiovasc Res 29 (1995) 80-84
29. Amati L., Caradonna L., Magrone T., Manghisi C., Leandro G., Caccavo D., et al. In vitro effects of naloxone on T-lymphocyte-dependent antibacterial activity in hepatitis C virus (HCV) infected patients and in inflammatory bowel disease (IBD) patients. Immunopharmacol Immunotoxicol 23 (2001) 1-11
30. Gekker G., Lokensgard J.R., and Peterson P.K. Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4+ lymphocyte cultures. Drug Alcohol Depend 64 (2001) 257-263
31. Halford W.P., Balliet J.W., and Gebhardt B.M. Re-evaluating natural resistance to herpes simplex virus type 1. J Virol 78 (2004) 10086-10095
32. Koelle D.M., and Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16 (2003) 96-113
33. Bamdad T., Roostaee M.H., Sadeghizadeh M., Mahboudi F., Kazemnejad A., and Soleimanjahi H. Immunogenicity and protective effect of a DNA construct encoding certain neutralizing epitopes of herpes simplex virus type-1 glycoprotein B. Folia Biol (Praha) 51 (2005) 109-113
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63